Skip to main content

Advertisement

Table 3 Odds ratio (95 % CI) by direct comparison (left lower part) and network meta- analysis (right upper part) based on safety

From: Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis

TwHF 1.21 (0.10–14.26) 0.19 (0.02–2.07) 0.11 (0.01–1.36) 0.66 (0.00–1.64e+28) 0.35 (0.03–3.74) 0.36 (0.04–3.85)
0.32 (0.03–3.19) MTX 0.16 (0.06–0.40) 0.09 (0.03–0.31) 0.55 (0.00–1.31e+28) 0.29 (0.11–0.73) 0.30 (0.14–0.68)
0.74 (0.49–1.10) LEF 0.58 (0.20–1.66) 3.48 (0.00–8.25e+28) 1.82 (0.93–3.54) 1.92 (1.18–3.13)
0.39 (0.16–1.01) 0.71 (0.40–1.25) 0.93 (0.51–1.36) SSZ 6.02 (0.00–1.43e+29) 3.15 (1.11–8.91) 3.33 (1.29–8.33)
2.06 (0.35–12.06) CsA 0.52 (0.00–1.27e+33) 0.55 (0.00–100.0)
FK506 1.05 (0.67–1.67)
0.37 (0.01–9.98) 0.30 (0.14–0.68) 3.00 (1.87–4.83) 3.32 (1.30–8.45) 1.03 (0.65–1.61) Placebo
  1. Results of direct comparisons are listed in the lower-left triangle, and the estimation is calculated as the row-defining treatment compared with the column-defining treatment. Results of network meta-analysis are listed in the upper-right triangle, and the estimation is calculated as the column-defining treatment compared with the row-defining treatment
  2. TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline